Escolar Documentos
Profissional Documentos
Cultura Documentos
October 2018
P I O N E E R I N G I M M U N O T H E R A P Y. T R A N S F O R M I N G L I V E S .
Disclaimer
Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Aduro or any director,
employee, agent, or adviser of Aduro. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.
The content of this presentation is subject to copyright, which will be asserted by Aduro, and no part of this presentation may be reproduced, stored in a retrieval
system, or transmitted in any form or by any means without prior permission in writing from Aduro.
2
Aduro Corporate Highlights
Robust Patent
Position Broad intellectual property portfolio covering STING and B-Select antibodies
3
Advancing a Robust R&D Pipeline of Innovative Programs
Out-
Anti-CD27 agonist CD27 Oncology
licensed
4
ADU-S100
STING Agonist
STING Plays a Critical Role in Activation of Tumor Immunity
6
ADU-S100 (MIW815): First-in-Class STING Agonist
ADU-S100 More Active than Naturally Occurring CDN ADU-S100 More Active Than TLR Agonists
2500 HBSS
2000 control
control
Days Post Injection of Tumor Cells Days Post Injection of Tumor Cells
8
ADU-S100 Induces Systemic Tumor Rejection in Preclinical Model
Mouse Lung Metastases Following IT Injection of Primary Tumor
50
Control Groups: (N=8)
P<0.001
HBSS control
40 ADU-S100
30
20
ADU-S100
10
0
Control ADU-S100
9
ADU-S100 and anti-PD-1 Synergize to Control Distal Tumors in Preclinical Model
4T1 Mammary Carcinoma Model HBSS Control + αPD-1 Low Dose ADU-S100 + αPD-1
HBSS + αPD-1 Low Dose
2500 ADU-S100 + αPD-1
2000
Primary Tumor
Primary Tumor
Tumor Volume [mm3]
2000
0 0
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
Days Post Tumor Challenge Days Post Tumor Challenge
2500 2000
Distal Tumor
Tumor Volume [mm ]
0 0
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
Days Post Tumor Challenge Days Post Tumor Challenge
10
Expanded ADU-S100 (MIW815) Clinical Development Plan
11
BION-1301
APRIL Antibody
MM Cell Survival and Proliferation Enhanced by APRIL Produced in
Bone Marrow Niche
13
BION-1301: First-in-Class APRIL Antibody
16
Upcoming Anticipated Milestones
H2 H1
2018 2019
17